In utero exposure to ADHD drugs not linked to developmental disorders
The Brown University Psychopharmacology Update May 28, 2023 DOI: 10.1002/pu.31038 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Key findings | The abstract describes the methods—measuring expected and actual changes in 18 affective states, collecting adverse events, and evaluating blinding via participant guesses—but reports no findings. |
Abstract
expected the microdosing to change how they felt on measures of 18 affective states: angry, anxious, calm, cognitive functioning, craving, creative, connected, energy, focused, guilty, happy, meditative, motivated, open, sad, self-efficacy, stressed, and well. They were asked at the final visit to report whether microdosing actually did result in change in these states. Data on adverse events were collected. The investigators evaluated blinding on each dose day by asking participants to guess whether they had received LSD or placebo.